Table 1.

Clinicopathological summary of the eight CD15+ nodular lymphocyte-predominant Hodgkin lymphomas (NLPHLs)

Case no.	Age ⁄ Sex	Pattern(s)*	Treatment(s)	Response	Outcome	Follow-up (months)
1	36 ⁄ M	C ⁄ D	–	–	–	–
2	49 ⁄ M	A	–	–	–	–
3	77 ⁄ F	C ⁄ E	R-CEOP	–	Dead	5
4	55 ⁄ M	D	ABVD ⁄ RT	–	Dead	1
5	62 ⁄ M	A ⁄ D	RICE	–	Dead	18
6	46 ⁄ M	E ⁄ A	R-CHOP	–	Alive	3
7	68 ⁄ M	D ⁄ E	ABVD	Partial response	Dead	0.7
8	26 ⁄ M	C ⁄ D	ABVD ⁄ EPOCH-R ⁄ RT ⁄ BMT	No response	Alive	60

^*Cases were classified on the basis of the patterns of NLHPL described by Fan et al., denoting predominant/less predominant pattern.

ABVD, Doxorubicin, bleomycin, vinblastine and dacarbazine; EPOCH-R, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab; R-CEOP, rituximab with cisplastin, etoposide, cyclophosphamide and vincristine; R-CHOP, rituximab with cyclophosphamide, adriamycin, vincristine, and prednisone with rituximab; RICE, rituximab, ifosfamide, carboplatin and etoposide; RT, radiotherapy; BMT, bone marrow transplant.